$STOCK UNDERGROUND$

[My4ntoy]

LPTN .81 - check this out!!!!

LPTN: Lpath (LPTN.OB) already has the attention of a powerhouse pharmaceutical giant, and that relationship only fuels the speculation that Pfizer (PFE) might make the ultimate jump and buy out its small time partner now, while the company is still considered cheap.

Lpath has developed a technology, through its proprietary ImmuneY2 platform, that generates antibodies that target bioactive lipids and inhibit the growth and spreading of various diseases and inflammatory/auto-immune disorders.

Advancements in the field of bioactive lipids have been gaining traction in the medical community over recent years, and Lpath is the only company to take it as far as it has. That success is what undoubtedly brought Pfizer to the bargaining table and landed Lpath a very significant deal for a Phase II company from a global behemoth.

Pfizer is already partnered for Lpath's iSONEP, a potential treatment for retinal pigment epithelium detachment ("RPE detachment" or "PED") and Wet AMD, but the licensing agreement also grants Pfizer the first right of refusal for ASONEP, a potential treatment for various cancer types.

Big players don't jump on still-developing companies without having a great deal of confidence in the technology behind the pipeline, which is sure to fuel takeover speculation regarding Pfizer and Lpath.

http://seekingalpha.com/article/310501-10-buyout-candidates-to-watch